The real-life impact of vaccination on COVID-19 mortality in Europe and Israel

Katarzyna Jabłońska¹, Samuel Aballéa², Mondher Toumi³

¹ MSc, Creativ-Ceutical, ul. Przemysłowa 12, 30-701 Kraków, Poland, katarzyna.jablonska@creativ-ceutical.com

² PhD, Creativ-Ceutical, Westblaak 90, 3012KM Rotterdam, Netherlands, samuel.aballea@creativ-ceutical.com

³ Prof., Faculty of Medicine, Public Health Department, Aix-Marseille University, 27 Boulevard Jean Moulin, Marseille 13005, France, mondher.toumi@univ-amu.fr

Corresponding author:

Katarzyna Jabłońska
Creativ-Ceutical, Ul. Przemysłowa 12, 30-701 Kraków, Poland
Phone: +33 17 670 47 90
E-mail: katarzyna.jablonska@creativ-ceutical.com

Declaration of interests:

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interests: None.

Acknowledgements: None.

Ethical approval: Not required. This study does not require ethical approval as it was conducted on country-level data and involved information freely available in the public domain.

Contributors:

MT conceptualized the study, KJ and SA validated the study concept, KJ and SA collected and analysed the data, KJ, SA and MT interpreted the results, KJ wrote the first draft of the manuscript, KJ, SA and MT revised the manuscript and approved the final version.

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel

Abstract

OBJECTIVES: This study aimed at estimating the real-life impact of vaccination on COVID-19 mortality, with adjustment for SARS-CoV-2 variants spread and other factors across Europe and Israel.

METHODS: Time series analysis of daily number of COVID-19 deaths was performed using non-linear Poisson mixed regression models. Variants' frequency, demographic, climate, health and mobility characteristics of thirty-two countries were considered as potentially relevant adjustment factors between January 2020 and April 2021.

RESULTS: The analysis revealed that vaccination efficacy in terms of protection against deaths was equal to 72%, with a lower reduction of number of deaths for B.1.1.7 versus non-B.1.1.7 variants (70% and 78%, respectively). Other factors significantly related to mortality were arrivals at airports, mobility change from the pre-pandemic level and temperature.

CONCLUSIONS: Our study confirms a strong effectiveness of COVID-19 vaccination based on real-life public data, although lower than expected from clinical trials. This suggests the absence of indirect protection for non-vaccinated individuals. Results also show that vaccination effectiveness against mortality associated with the B.1.1.7 variant is slightly lower compared with other variants. Lastly, this analysis confirms the role of mobility reduction, within and between countries, as an effective way to reduce COVID-19 mortality and suggests the possibility of seasonal variations in COVID-19 incidence.

Keywords: COVID-19 mortality, SARS-CoV-2 variants, B.1.1.7 variant, VOC, vaccination, mobility.

Introduction

The pandemic of the coronavirus infectious disease 2019 (COVID-19) is continuously evolving, driven by the spread of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). During the second half of 2020 and early 2021 variety of new SARS-CoV-2 variants emerged. EU2 variant (mutation S:447N) firstly observed in July 2020 in western Europe, was found to be capable of increasing virus infectivity.^{1,2} Then, several variants of concern (VOC) have been identified, including B.1.1.7 developed firstly in the UK in September 2020,³ B.1.351 in South Africa in December 2020,⁴ P.1 in Brazil in January 2021,⁵ and the 'Indian' variant B.1.617 reported firstly in Maharashtra in January 2021.⁶ The disease mortality has been increased in these countries after new variants were developed.⁷⁻¹⁰ An increased risk of transmissibility, hospitalization and death associated with the B.1.1.7 variant was reported by number of authors.^{8,11-16} The B.1.351 variant was found to have an increased transmissibility and immune escape,¹⁷ and was estimated to be 50% more transmissible than preexisting variants.¹⁸ Higher incidence of COVID-19 cases in younger age groups were observed in the Amazonas state, suggesting changes in pathogenicity of the P.1 variant.¹⁹ Preliminary findings suggest also a significant increase in case fatality rate in young and middle-aged for the P.1 mutant.²⁰ The region of Maharashtra, where the B.1.617 variant emerged, experienced significant rise in daily infection rate after the new variant appeared.¹⁰

To control the SARS-CoV-2 spread, numbers of different vaccines have been developed and analyzed in clinical trials, including eight vaccines having emergency use or conditional marketing authorizations worldwide or across regions, as of May 2021.²¹ The worldwide vaccination campaign has started in December 2020 aiming to provide herd immunity across societies. The threshold for COVID-19 "herd immunity" was placed between 60–70% of the population gaining immunity through vaccinations or past disease exposure, however, scientists warn that herd-

immunity is unlikely to be achieved due to factors such as vaccine hesitancy and the spread of new variants.^{22,23} Israel was far ahead of other countries in terms of the proportion of vaccinated inhabitants, exceeding 62% at the end of April 2021, with the UK reaching 50% and the USA 42% at the same time.²⁴

Results of clinical trials on vaccine efficacy revealed that Pfizer-BioNTech had 95% efficacy at preventing symptomatic COVID-19 infection in people without prior infection.²⁵ 94.1% efficacy was reported for Moderna,²⁶ 70.4% for Oxford-AstraZeneca,²⁷ 66.5% for Johnson & Johnson²⁸ and 96.4% for Novavax,²⁹ with the latter being still under the investigation before authorization. For the prevention against a severe disease course, Pfizer, Moderna, AstraZeneca and Novavax reported a 100% efficacy, whereas 84% was observed for Johnson & Johnson, however, the latter was tested on a broader range of countries, including the USA, South Africa and Brazil, after the new VOCs spread.

Clinical evidence suggests that newly developed virus variants may affect the protective efficacy of both naturally acquired immunity and of vaccinations. Studies on neutralization of convalescent sera against distinct strains showed that VOCs were harder to neutralize than the original strain, an early Wuhan-related strain of SARS-CoV-2. Neutralization titers against the B.1.1.7 variant showed a 3-fold reduction,³⁰ a 3.4-fold reduction was observed for the P.1 variant,³¹ and a 13.3-fold reduction for the B.1.531 variant.³² Johnson & Johnson vaccine was found to have 64% efficacy against infection in South Africa and 68% in Brazil after the spread of B.1.135 and P.1 variants, whereas the efficacy against severe-critical disease was 82% and 88% in both countries, respectively.²⁸ Late March 2021, AstraZeneca was observed as having 70.4% efficacy against the B.1.1.7 variant,³³ however, the vaccine did not protect as well against B.1.351 variant.³⁴ For Novavax, the initial evidence suggests 86.3% efficacy against B.1.1.7 variant³⁵ and 49.4% against B.1.351.³⁶ Early May 2021, Pfizer vaccine was found to be 87% effective against infection with B.1.1.7 variant and 72% against B.1.351 variant, whereas 97.4% efficacy against severe disease course was observed for any of these mutations.³⁷ On the other hand, Wang (et al.) observed a reduced neutralization of Moderna and Pfizer vaccine-immune sera against B.1.351 variant (12.4-fold for Moderna; 10.3-fold for Pfizer), but no significant impact was observed for B.1.1.7 variant.³⁸ Next, a 3.8-4.8-fold reduced neutralization of Moderna vaccine was observed against P.1 variant.³¹ Preliminary evidence suggests a significant drop in neutralization of B.1.617 compared to other variants, including B.1.1.7 and P.1, with sera of Indian's vaccine, Covaxine.¹⁰

The other concern is the probability of re-infection after recovery or vaccination. Hansen (et al.) observed an 80.5% protection against re-infection in a population-level observational study on Danish patients previously tested positive for SARS-CoV-2,³⁹ however, the study was performed before VOCs spread. The probability of re-infection after vaccination is also a big concern. As reported by the USA Centers for Disease Control and Prevention (CDC), there were around 9200 infections among vaccinated inhabitants among 95 million of those who have already been vaccinated in the USA (0.01%) as of 26 April 2021.⁴⁰ Despite this optimistic preliminary data, effects of vaccination were not reliably assessed in a longer perspective thus far. The real-world evidence on vaccination effectiveness is still sparse. Experts alarm that additional data are needed to assess the potential impact of VOCs on future vaccine efficacy.⁴¹ Considering all the concerns associated with new VOCs spread, the real vaccination effectiveness becomes hard to assess and prognose but can be expected to decrease over time. Also, it is likely that vaccination may favour the emergence of new variants by selection of new, better fitted mutants. Some scientists suggest that, similarly as for seasonal flu vaccines, COVID-19 vaccines will need to be redesigned or even updated periodically to protect against new variants.^{42,43}

Vaccination efficacy and distinct variants spread are only two factors among numerous other variables affecting COVID-19 infection and death rates across the world. A variety of potential predictors were assessed in the literature, including demographic characteristics, mobility and social-distancing measures, environmental and climate variables, as well as health characteristics.⁴⁴⁻⁵³

This study aims at estimating the real-life impact of vaccination on COVID-19 mortality based on publicly available data from Europe and Israel, using time series analysis with non-linear mixed regression models. Variants

frequency, including B.1.1.7 and other variants, as well as country-specific demographic and meteorological characteristics, health indicators and mobility factors were considered as potentially relevant adjustment factors. Results of the current study should inform policy decision makers, scientists, and the general public about the role of vaccination and social-distancing strategies in controlling the COVID-19 pandemic in the face of new VOCs spread.

Methods

Data collection

A total of 32 countries were considered in the analysis, including European countries and Israel. The daily number of COVID-19 deaths was the primary outcome of interest. Values were smoothed using 7-day moving average, divided by the number of inhabitants of a given country and reported as daily numbers of deaths per 1 million inhabitants.

The main explanatory variables of interest were proportion of vaccinated inhabitants (vaccination coverage), as well as average proportions of SARS-CoV-2 variants calculated across strains forming twelve Nextstrain clades. The focus was on 20A (EU2), 20E (EU1) and 20I (B.1.1.7) variants, with two formers being dominant in Europe during the summer 2020, and the latter VOC being most frequent early 2021. Other time-varying covariates considered in the analysis were maximum daily temperature, mean daily wind speed, number of arrivals at two biggest airports of a country and change in mobility from pre-pandemic level (considering the average across retail/recreation, transit stations and groceries/pharmacies). Additional fixed covariates were proportion of population aged 65 or more, prevalence of diabetes and rate of cardiovascular deaths.

Data on COVID-19 deaths and vaccination were obtained from Our World In Data on 15 April 2021.²⁴ Meta-data on SARS-CoV-2 virus variants (clades) identified up to mid-April 2021 was downloaded from the Nextstrain platform.⁵⁴⁻⁵⁶ We assumed that if a strain was observed on a given date, it could be observed in a range of ± 14 days from the observation date. Since the data were not reported daily, linear interpolation was used to impute missing observations, assuming zeros a month before the first and after the last (if up to 1 March 2021) reported occurrence of a variant. Finally, data were smoothed with the use of 14-day moving average.

Countries' characteristics were obtained from Our World In Data, Eurostat, National Centers for Environmental Information, Aviation Intelligence Portal and Google COVID-19 Community Mobility Reports.^{24,57-60} Data on arrival flights and mobility were smoothed using 7-day moving average.

Statistical analysis

Regression analysis was used to investigate the association between COVID-19 mortality and daily reported time-varying variables and fixed covariates.

The primary analysis of daily number of COVID-19 deaths was performed with the use of non-linear Poisson mixed model with random country-level intercept and mobility effects. The considered period was from the date of first reported death in Europe, 29 January 2020, up to 15 April 2021.

Due to the presence of autocorrelations, and to consider the fact that the number of infections on a given day is dependent on the number of infectious cases in the population over previous days, the model was adjusted for the logarithm of daily number of COVID-19 deaths reported 7 days earlier. To capture the fact that increasing or decreasing trends in COVID-19 mortality over time are generally stable over several weeks or months, the logarithm of quotient of COVID-19 deaths 7 days before divided by deaths 14 days before the actual date was added as a covariate. All other time-varying variables were considered with a 21-day lag, to account for the virus incubation period and the delay between being infected and die due to the disease. In addition, heterogeneity between countries was considered with random intercepts and mobility effects varying between countries.

Assuming M indicates mortality with a vaccination coverage ‘ c ’, M_0 is the mortality without vaccination and ‘ VE ’ represents the vaccine efficacy, we have:

$$M = M_0 \cdot (1 - c \cdot VE).$$

After applying the logarithmic transformation and considering a set of covariates $x_1, \dots, x_k$ and random effects $u_0, u_1, \dots, u_n$ on intercept and selected $x_1, \dots, x_n$, the equation above was extended as shown below to specify the non-linear model:

$$\text{Log}(E(M)) = \beta_0 + \text{Log}((1 - c \cdot VE)) + \beta_1 x_1 + \dots + \beta_k x_k + u_0 + u_1 x_1 + \dots + u_n x_n.$$

For the exploratory analysis, vaccine efficacy against B.1.1.7 and non-B.1.1.7 variants was analyzed using a similar approach. Assuming that there are two classes of virus variants with known proportions equaled p_1 and p_2 , the vaccine efficacy could be considered as the average efficacy weighted by variants proportions:

$$VE = p_1 \cdot VE_1 + p_2 \cdot VE_2.$$

The formula for the non-linear model is then as follows:

$$\text{Log}(E(M)) = \beta_0 + \text{Log}((1 - c \cdot (p_1 \cdot VE_1 + p_2 \cdot VE_2))) + \beta_1 x_1 + \dots + \beta_k x_k + u_0 + u_1 x_1 + \dots + u_n x_n.$$

A p-value lower than 0.05 was considered as statistically significant. Akaike’s Information Criterion (AIC) was provided to inform about models’ fit statistic. Analyses were performed using SAS 9.4 software.

Results

Descriptive statistics

Descriptive statistics of outcomes and covariates across 32 countries included in the analysis, for the period between January 2020 and April 2021 are presented in Table 1. Cumulative numbers of COVID-19 deaths per inhabitant across countries during this period are presented in Figure 1. The highest numbers were observed for central and south-east countries: Czechia, Hungary, Bosnia and Herzegovina. Mean proportions of SARS-CoV-2 variants, EU2, EU1 and B.1.1.7 for each country are presented in Figure 2. Up to mid-April 2021, the variant EU2 was the most frequently spread for vast majority of countries, except Israel and the UK for which B.1.1.7 was more frequent, as well as Spain and Lithuania with EU1 being more commonly observed.

Primary analysis

Analysis of the non-linear Poisson mixed model of number of COVID-19 deaths revealed that the effect of vaccination efficacy against mortality was assessed as significant and equalled to 0.720 ($p < 0.001$; Table 2). Other covariates which were found significant in the model were: temperature (-0.005 , $p < 0.001$), arrivals at airports (0.709 , $p < 0.001$) and mobility change from pre-pandemic level (0.753 , $p < 0.001$). Variables used to account for autocorrelation and minimize the effect of trend were assessed as significant (Log of number of daily COVID-19 deaths: 0.926 , $p < 0.001$; Log of number of COVID-19 deaths 7 days before / 14 days before: 0.158 , $p < 0.010$).

Exploratory analysis

Results of the analysis of the exploratory model revealed numerically lower vaccine efficacy against B.1.1.7 than against non-B.1.1.7 variants, although the difference was not statistically significant (0.697 , $p = 0.002$ and 0.778 , $p = 0.049$, respectively; Table 3). The same set of covariates were found significant in the exploratory model as in the primary analysis: temperature (-0.005 , $p < 0.001$), arrivals at airports (0.703 , $p < 0.001$) and mobility change from pre-pandemic level (0.753 , $p < 0.001$). Variables used to account for autocorrelation and minimize the effect of trend were assessed as significant (Log of number of daily COVID-19 deaths: 0.926 , $p < 0.001$; Log of number of COVID-19 deaths 7 days before / 14 days before: 0.158 , $p < 0.010$).

Discussion

In this study we investigated the association between daily mortality due to COVID-19 and vaccination coverage, proportions of SARS-CoV-2 variants and additional factors, such as demographics, health, mobility and meteorological variables, analyzing country-level data across Europe and Israel. Results of the analysis suggest that vaccination effectiveness against deaths is equal to 72%, and that it is slightly lower against the B.1.1.7 variant compared to non-B.1.1.7 variants (difference not statistically significant). These findings suggest lower effectiveness against death than reported efficacy against severe or critical disease course in clinical trials of vaccines (84-100%).²⁵⁻²⁹

This lower than expected effectiveness might be explained by the difference in considered populations: clinical trials included restrictive populations and our study covers general populations, irrespective of age, concomitant therapies, medical condition and general condition. In particular, vaccinated people in real life are older on average than subjects enrolled in clinical trials (12.2% aged ≥ 55 in AstraZeneca trial; 24.7% aged ≥ 65 in Moderna trial; 33.5% aged ≥ 60 in Johnson & Johnson trial; 42.3% aged ≥ 55 in Pfizer trial). However, our results suggesting lower protection against B.1.1.7 variant, are consistent with reported data so far from in vivo experiments and patient level studies, providing an external validation of these findings. Laboratory evidence revealed a slight reduction in neutralization against B.1.1.7 variant compared to the original strain. Neutralization titers against this VOC were 3-fold lower when analyzing convalescent sera, and 3.3-fold and 2.5-fold lower for Pfizer and AstraZeneca vaccinees, respectively.³⁰ Real-world studies on B.1.1.7 VOC suggested that it caused increased mortality compared to non-B.1.1.7 variants,^{15,61} which, therefore, might not have been contained with similar effectiveness by vaccination. Our results evoke the question of variants evading vaccine antibodies in the future and the need to adapt such vaccine for each new season, which was earlier suggested by experts.^{42,43}

While the utilization of individual-level data, collected in real-world setting, could provide more precise estimates of vaccine effectiveness, the use of aggregate data at country level also has a major advantage: the vaccination impact estimated in this analysis should capture the indirect protection provided by vaccination. If the vaccine protects against infection, the number of infectious cases would decrease as more people are vaccinated. The lower number of infectious cases in the population would lead to a reduced probability for susceptible individuals to get in contact with infectious cases, thus leading to a reduction in incidence among all people, including non-vaccinated people. This indirect protection can be captured when comparing different populations with different rates of vaccination coverage, but could not be captured when comparing vaccinated and non-vaccinated individuals from the same population. Interestingly, the fact that our estimated vaccine effectiveness is relatively low compared to vaccine efficacy reported in clinical trials suggests that there is no or little indirect protection provided by vaccination. This could indicate that the vaccine protects against disease but not against infection, or that vaccinated groups of population are not those that contribute to the propagation of the virus.

A positive relationship between number of arrivals at airports and mortality has been observed in this analysis, similarly as between mobility change and mortality. It suggests that both increased long-distance travel and increased mobility are strong predictors of growth in daily number of COVID-19 deaths. These findings highlight the role of mobility reduction, both within and between countries, as an effective way to reduce COVID-19 mortality, especially when new virus variants emerge and spread across the world. Our results are in line with previous study by Jabłońska (et al.) suggesting that countries with lower reduction in mobility at the beginning of the pandemic experienced a higher COVID-19 daily deaths peak.⁵⁰ The role of social distancing was also underlined by Badr (et al.) who observed a significant impact of mobility on COVID-19 transmission in the USA.⁶²

The daily temperature was found as a significant predictor of COVID-19 mortality in this study, with increasing temperature associated with the reduction in number of deaths. Kerr (et al.) found no consensus on the impact of meteorological factors on COVID-19 spread in their literature review, however, they suggested existence of environmental sensitivity of COVID-19, but not as significant as non-pharmaceutical interventions and human

behavior.⁶³ Several authors underlined that disease seasonality may exist,⁶⁴⁻⁶⁷ including Liu (et al.) who found that COVID-19 infection and mortality rates were higher in colder climates and that the cold season caused an increase in total infections, while the warm season contributed to the opposite effect.⁶⁶ Since our analysis covered a full annual cycle of COVID-19, our result suggests the possibility of seasonal variations in COVID-19 incidence. Such seasonality has been well established in temperate climate for other respiratory viruses.^{68,69}

Limitations

Our study has several limitations. Firstly, our analysis was conducted on a country-level basis to estimate the vaccination efficacy, which should be seen as less precise method compared to analysis of individual-level data, as previously noted. However, given the range of included countries, our results shed light on the problem of vaccination effectiveness from a broader perspective and investigate the effect of vaccination across societies, considering variability of vaccination coverage through time and between countries. Secondly, the quality of data on variants distribution varied between countries and was low for some of them, therefore, results of the exploratory analysis should be treated with caution. To limit bias and avoid fluctuations, we employed methods of interpolation and smoothing. Countries with limited data were excluded. Thirdly, the set of covariates used in the multivariate analysis can be assessed as non-exhaustive. We decided to consider factors which were previously assessed as significantly impacting the risk of severe illness or mortality from COVID-19 in the literature.⁵⁰⁻⁵³ Finally, we were not able to consider other new SARS-CoV-2 VOCs, except B.1.1.7, in the current analysis, which was due to their limited spread in Europe as of April 2021. It rises a need for further research on this topic in the future.

Conclusions

This study confirms a strong effectiveness of COVID-19 vaccination based on real-life public data, in terms of protection against deaths being around 72%, although it appears to be slightly lower than could be expected from clinical trial results. This suggests the absence of indirect protection for non-vaccinated individuals. Results also suggest that vaccination effectiveness against mortality associated with the B.1.1.7 variant is high but slightly lower compared with other variants (70% and 78%, respectively). Finally, this analysis confirms the role of mobility reduction, both within and between countries, as an effective way to reduce COVID-19 mortality and supports the possibility of seasonal variations in COVID-19 incidence.

References

1. Liu Z, VanBlargan LA, Rothlauf PW, et al. Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. *bioRxiv* 2020: 2020.11.06.372037.
2. Hodcroft EB. CoVariants: SARS-CoV-2 Mutations and Variants of Interest. 2021. <https://covariants.org/> (accessed 15th March 2021).
3. Rambaut A, Loman N, Pybus O. Preliminary Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in the UK Defined by a Novel Set of Spike Mutations. <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563> (accessed 15th March 2021).
4. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *medRxiv* 2020: 2020.12.21.20248640.
5. Faria N, Claro I, Candido D, et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. 2021. <https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586> (accessed 21 April 2021).
6. Barnagarwala T, Mascarenhas A. Explained: B.1.617 variant and the Covid-19 surge in India. 2021. <https://indianexpress.com/article/explained/maharashtra-double-mutant-found-b-1-617-variant-and-the-surge-7274080/> (accessed 27 April 2021).

7. Naveca F, da Costa C, Nascimento V. SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P.1 in Amazonas, Brazil. 2021. <https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-amazonas-brazil/596> (accessed 16th March 2021).
8. Iacobucci G. Covid-19: New UK variant may be linked to increased death rate, early data indicate. *BMJ* 2021; **372**: n230.
9. Jassat W, Mudara C, Ozougwu L, et al. Increased mortality among individuals hospitalised with COVID-19 during the second wave in South Africa. *medRxiv* 2021: 2021.03.09.21253184.
10. Yadav PD, Sapkal GN, Abraham P, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. *bioRxiv* 2021: 2021.04.23.441101.
11. Wallace DJ, Ackland GJ. Abrupt increase in the UK coronavirus death-case ratio in December 2020. *medRxiv* 2021: 2021.01.21.21250264.
12. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ* 2021; **372**: n579.
13. New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG). Resport to SAGE: Increased disease severity in people infected with variant of concern (VOC) B.1.1.7 compared to people infected with non-VOC virus variants. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf (accessed 15th March 2021).
14. Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 7. 11th March 2021. <https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201>, https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/968581/Variants_of_Concern_VOC_Technical_Briefing_7_England.pdf (accessed 15th March 2021).
15. Davies NG, Jarvis CI, van Zandvoort K, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. *Nature* 2021.
16. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* 2021; **372**(6538): eabg3055.
17. Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* 2021; **592**(7854): 438-43.
18. Pearson C, Russell T, Davies N, et al. Estimates of severity and transmissibility of novel SARS-CoV-2 variant 501Y.V2 in South Africa.
19. Freitas ARR, Beckedorff OA, de Góes Cavalcanti LP, Siqueira AM, et al. The emergence of novel SARS-CoV-2 variant P.1 in Amazonas (Brazil) was temporally associated with a change in the age and gender profile of COVID-19 mortality. 2021.
20. de Oliveira MHS, Lippi G, Henry BM. Sudden rise in COVID-19 case fatality among young and middle-aged adults in the south of Brazil after identification of the novel B.1.1.28.1 (P.1) SARS-CoV-2 strain: analysis of data from the state of Parana. *medRxiv* 2021: 2021.03.24.21254046.
21. The New York Times. Coronavirus Vaccine Tracker. 2021. <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html> (accessed 12 May 2021).
22. Aschwanden C. Five reasons why COVID herd immunity is probably impossible. 2021. <https://www.nature.com/articles/d41586-021-00728-2> (accessed 27 April 2021).
23. Gu Y. Path to Normality: 2021 Outlook of COVID-19 in the US. 2021. <https://covid19-projections.com/path-to-herd-immunity/> (accessed 27 April 2021).
24. Our World In Data. Coronavirus (COVID-19) Vaccinations. 2021. <https://ourworldindata.org/covid-vaccinations> (accessed 27 April 2021).
25. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine* 2020; **383**(27): 2603-15.
26. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *The New England journal of medicine* 2021; **384**(5): 403-16.

27. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet* 2021; **397**(10269): 99-111.
28. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *New England Journal of Medicine* 2021.
29. Novavax Inc. Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials. 11 March 2021 2021. <https://ir.novavax.com/news-releases/news-release-details/novavax-confirms-high-levels-efficacy-against-original-and-0>.
30. Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. *Cell* 2021; **184**(8): 2201-11.e7.
31. Wang P, Casner RG, Nair MS, et al. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. *bioRxiv* 2021: 2021.03.01.433466.
32. Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* 2021.
33. Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. *The Lancet* 2021; **397**(10282): 1351-62.
34. University of Oxford. ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults. 2021. <https://www.research.ox.ac.uk/Article/2021-02-07-chadox1-ncov-19-minimal-protection-against-mild-covid-19-from-b-1-351-variant-in-young-sa-adults> (accessed 27 April 2021).
35. Heath PT, Galiza EP, Baxter DN, et al. Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant. *medRxiv* 2021: 2021.05.13.21256639.
36. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. *New England Journal of Medicine* 2021.
37. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *New England Journal of Medicine* 2021.
38. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature* 2021; **593**(7857): 130-5.
39. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *The Lancet* 2021; **397**(10280): 1204-12.
40. Centers for Disease Control and Prevention. COVID-19 Breakthrough Case Investigations and Reporting. 2021. <https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html> (accessed 11 May 2021).
41. Sanders RW, de Jong MD. Pandemic moves and countermoves: vaccines and viral variants. *The Lancet* 2021; **397**(10282): 1326-7.
42. Callaway E, Ledford H. How to redesign COVID vaccines so they protect against variants. *Nature* 2021; **590**(7844): 15-6.
43. Bian L, Gao F, Zhang J, et al. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. *Expert Review of Vaccines* 2021: 1-9.
44. Aldibasi OS, Alharbi NK, Alkelya M, Zowawi H, Alghnam S. The Association of Country-Level Factors with Outcomes of COVID-19: Analysis of the pandemic after one million cases. *Research Square* 2020.
45. Burden SJ, Rademaker J, Weedon BD, Whaymand L, Dawes H, Jones A. Associations of Global Country Profiles and Modifiable Risk Factors with COVID-19 Cases and Deaths. *medRxiv* 2020: 2020.06.17.20133454.
46. Sorci G, Faivre B, Morand S. Why Does COVID-19 Case Fatality Rate Vary Among Countries? *The Lancet* 2020.
47. Garcia de Alcaniz JG, Romero-Lopez J, Martinez RP, Lopez-Rodas V, Costas E. What variables can better predict the number of infections and deaths worldwide by SARS-CoV-2? Variation through time. *medRxiv* 2020: 2020.06.04.20122176.

48. Woody S, Garcia Tec M, Dahan M, et al. Projections for first-wave COVID-19 deaths across the US using social-distancing measures derived from mobile phones. *medRxiv* 2020: 2020.04.16.20068163.
49. Courtemanche C, Garuccio J, Le A, Pinkston J, Yelowitz A. Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate. *Health Affairs*; **0**(0): 10.1377/hlthaff.2020.00608.
50. Jabłońska K, Aballéa S, Toumi M. Factors influencing the COVID-19 daily deaths' peak across European countries. *Public Health* 2021; **194**: 135-42.
51. Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its Impact on Patients with COVID-19. *SN Compr Clin Med* 2020: 1-8.
52. Centers for Disease Control and Prevention. COVID-19: People at increased risk with certain medical conditions. 2021. <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html> (accessed 15th March 2021).
53. Omar SA, Naif KA, Mohamed A, Hosam Z, Suliman A. The Association of Country-Level Factors with Outcomes of COVID-19: Analysis of the pandemic after one million cases. *Research Square* 2021.
54. Hadfield et al. Nextstrain: real-time tracking of pathogen evolution *Bioinformatics* 2018.
55. Bedford T, Neher R, Hadfield J, et al. Nextstrain - Real-time tracking of pathogen evolution. 2021. <https://nextstrain.org/> (accessed 15th March 2021).
56. Global Initiative on Sharing All Influenza Data (GISAI). The GISAI Initiative. <https://www.gisaid.org/> (accessed 14th March 2021).
57. Eurostat. Eurostat Database. 2021. <https://ec.europa.eu/eurostat/data/database> (accessed 29 April 2021 2021).
58. National Centers for Environmental Information. Global Surface Summary of the Day. 2021. <https://www.ncei.noaa.gov/access/search/data-search/global-summary-of-the-day> (accessed 15 April 2021).
59. EUROCONTROL. Aviation Intelligence Portal. 2021. <https://ansperformance.eu/data/> (accessed 15 April 2021 2021).
60. Google. COVID-19 Community Mobility Reports. 2021. <https://www.google.com/covid19/mobility/> (accessed 15 April 2021 2021).
61. Jabłońska K, Aballéa S, Auquier P, Toumi M. On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe. *medRxiv* 2021: 2021.03.25.21254289.
62. Badr HS, Du H, Marshall M, Dong E, Squire MM, Gardner LM. Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study. *The Lancet Infectious Diseases* 2020; **20**(11): 1247-54.
63. Kerr GH, Badr HS, Gardner LM, Perez-Saez J, Zaitchik BF. Associations between meteorology and COVID-19 in early studies: Inconsistencies, uncertainties, and recommendations. *One Health* 2021; **12**: 100225.
64. Merow C, Urban MC. Seasonality and uncertainty in global COVID-19 growth rates. *Proceedings of the National Academy of Sciences* 2020; **117**(44): 27456-64.
65. Engelbrecht FA, Scholes RJ. Test for Covid-19 seasonality and the risk of second waves. *One Health* 2021; **12**: 100202.
66. Liu X, Huang J, Li C, et al. The role of seasonality in the spread of COVID-19 pandemic. *Environ Res* 2021; **195**: 110874-.
67. Audi A, Allbrahim M, Kaddoura M, Hijazi G, Yassine HM, Zaraket H. Seasonality of Respiratory Viral Infections: Will COVID-19 Follow Suit? *Frontiers in Public Health* 2020; **8**(576).
68. Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. *Annual Review of Virology* 2020; **7**(1): 83-101.
69. Martinez ME. The calendar of epidemics: Seasonal cycles of infectious diseases. *PLOS Pathogens* 2018; **14**(11): e1007327.

Tables

Table 1. Descriptive statistics of outcomes and covariates across 32 countries (January 2020 – April 2021)

Variable	N	Mean	Standard Deviation	Median	Lower Quartile	Upper Quartile	Minimum	Maximum
Number of daily COVID-19 deaths	13229	3.355	4.618	1.159	0.206	4.933	0	28.770
Proportion of vaccinated inhabitants	13181	0.018	0.058	0	0	0	0	0.616
Proportion of 20A (EU2) variant	13106	0.349	0.250	0.313	0.154	0.509	0	1.000
Proportion of 20E (EU1) variant	12754	0.090	0.159	0	0	0.114	0	0.741
Proportion of 20I (B.1.1.7) variant	13099	0.124	0.256	0	0	0.065	0	1.000
Max daily temperature	13008	15.597	9.347	15.833	8.750	22.389	-17.111	43.111
Mean daily wind speed	13010	6.227	3.353	5.600	3.700	8.100	0.100	25.800
Arrivals at two biggest airports	12748	140.609	195.648	66.429	27.714	177.929	1.857	1780.143
Mobility change from pre-pandemic ¹	12918	-0.217	0.170	-0.201	-0.322	-0.091	-0.792	0.199
Proportion of inhabitants aged ≥65	13229	0.184	0.025	0.190	0.168	0.198	0.117	0.230
Diabetes prevalence	13229	0.062	0.019	0.058	0.048	0.072	0.033	0.101
Cardiovascular death rate	13229	2.037	1.124	1.535	1.148	2.783	0.861	5.398

¹ Average mobility change from pre-pandemic calculated across retail/recreation, transit stations and groceries/pharmacies [0.01]. Descriptive statistics were calculated for 32 countries based on daily data between 29 January 2020 and 15 April 2021.

Table 2. Results of the non-linear Poisson mixed model of number of daily COVID-19 deaths

Variable	Estimate	Standard Error	P value
Intercept	0.467	0.202	0.028
Logarithm of number of daily COVID-19 deaths [#]	0.926	0.007	<0.001
Logarithm of (number of COVID-19 deaths 7 days before / 14 days before)	0.158	0.015	<0.001
Proportion of 20A (EU2) variant*	0.012	0.036	0.746
Proportion of 20E (EU1) variant*	-0.032	0.046	0.501
Proportion of 20I (B.1.1.7) variant*	0.059	0.033	0.084
Max daily temperature*	-0.005	0.001	<0.001
Mean daily wind speed*	-0.002	0.002	0.351
Arrivals at two biggest airports [in thousands]*	0.709	0.085	<0.001
Mobility change from pre-pandemic ^{*1}	0.753	0.064	<0.001
Proportion of inhabitants aged ≥65 [^]	-1.238	0.930	0.193
Diabetes prevalence [^]	0.544	1.293	0.677
Cardiovascular death rate [^]	0.023	0.023	0.322
Vaccination efficacy*	0.720	0.132	<0.001
Variance for RE on intercept	0.014	0.006	0.023
Variance for RE on mobility	0.036	0.023	0.126

[#]Time-varying variable with a 7-days lag.

* Time-varying variable with a 21-days lag.

[^]Fixed variable.

¹ Average mobility change from pre-pandemic calculated across retail/recreation, transit stations and groceries/pharmacies [0.01].

Abbreviations: AIC = Akaike's Information Criterion; mln = million; RE = random effects.

Non-linear Poisson mixed model of daily number of COVID-19 deaths per 1 mln inhabitants, with country-specific random effects on intercept and mobility. Daily data for 32 countries were included, from 29 January 2020 up to 15 April 2021.

Table 3. Results of the non-linear Poisson mixed model of number of daily COVID-19 deaths with interactions between variants proportions and vaccination efficacy

Variable	Estimate	Standard Error	P value
Intercept	0.409	0.204	0.054
Logarithm of number of daily COVID-19 deaths [#]	0.926	0.007	<0.001
Logarithm of (number of COVID-19 deaths 7 days before / 14 days before)	0.158	0.015	<0.001
Proportion of 20A (EU2) variant*	0.012	0.036	0.747
Proportion of 20E (EU1) variant*	-0.034	0.047	0.467
Proportion of 20I (B.1.1.7) variant*	0.059	0.033	0.085
Max daily temperature*	-0.005	0.001	<0.001
Mean daily wind speed*	-0.002	0.002	0.346
Arrivals at two biggest airports [in thousands]*	0.703	0.085	<0.001
Mobility change from pre-pandemic ^{*1}	0.753	0.064	<0.001

Variable	Estimate	Standard Error	P value
Proportion of inhabitants aged $\geq 65^{\wedge}$	-0.805	0.925	0.391
Diabetes prevalence [^]	0.124	1.285	0.924
Cardiovascular death rate [^]	0.025	0.023	0.278
Vaccination efficacy against 20I (B.1.1.7)*	0.697	0.201	0.002
Vaccination efficacy against variants other than 20I (B.1.1.7)*	0.778	0.379	0.049
Variance for RE on intercept	0.013	0.006	0.025
Variance for RE on mobility	0.035	0.023	0.132

AIC = 30186.

[#] Time-varying variable with a 7-days lag.

* Time-varying variable with a 21-days lag.

[^] Fixed variable.

¹ Average mobility change from pre-pandemic calculated across retail/recreation, transit stations and groceries/pharmacies [0.01].

Abbreviations: AIC = Akaike's Information Criterion; mln = million; RE = random effects.

Non-linear Poisson mixed model of daily number of COVID-19 deaths per 1 mln inhabitants, with country-specific random effects on intercept and mobility, including interactions between variants proportions and vaccination efficacy. Daily data for 32 countries were included, from 29 January 2020 up to 15 April 2021.

Figures

Figure 1. Cumulative number of COVID-19 deaths per 1 million inhabitants across countries

Cumulative number of COVID-19 deaths per one million inhabitants were calculated based on data on mortality between 29 January 2020 and 15 April 2021.

Figure 2. Mean SARS-CoV-2 variants proportions across countries, between January 2020 and April 2021

Mean proportions of variants were calculated based on daily data on variants proportions across observed strains used to form Nextstrain clades (variants), between 29 January 2020 and 15 April 2021.